Physician profile
Oscar E Rodas
NPI 1528002748
$7,864.31
in general payments reported to CMS, 2019-2025
44 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $473 · 2021: $2,115 · 2022: $1,529 · 2023: $1,057 · 2024: $755 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,198.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,155.33 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $929.17 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $830.30 | 2019-2021 | |
| Lilly USA, LLC | $517.42 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $439.48 | 2019-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $326.11 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $295.62 | 2019-2025 | |
| Dexcom, INC. | $290.62 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $280.71 | 2021-2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.49 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $188.10 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $158.81 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $147.85 | 2020-2024 | Veozah, Myrbetriq |
| Cvrx, INC. | $132.15 | 2022 | |
| Abiomed | $128.95 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Rodas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.